CTGCT project has received funding from the European Union’s Horizon Europe research and innovation programme (grant agreement No. 101059842) and UK Research and Innovation (UKRI) under the UK government’s Horizon Europe funding guarantee (grant number 10069462).

PROJECT COORDINATOR

Koordinator


ADVANCED PARTNERS

Partnerji V Projektu


FOUNDERS

Financerji 3


Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Executive Agency (REA). Neither the European Union nor the granting authority can be held responsible for them.

Cooperation

Znak Kemijskega Ins Tituta Copy~imageoptim

The National Institute of Chemistry contributes to the Centre’s cutting-edge expertise in the field of the development of therapeutics for cancer and genetic diseases in combination with synthetic biology.

Ucl

UCL has expertise in translation of biomedicine and will be a key international strategic partner. They advise on the organisation of the Centre, and support the transfer of therapies from laboratories to patients and the market.

Umc

UMC Utrecht has access to the latest technology providers and experience in the establishment of a GMP facility. Their knowledge is vital to setting up the such premises.

Tedresden

TU Dresden provides expertise, technology and equipment for gene editing and regeneration towards new therapies such as neurodegenerative and haematological diseases.

Charite

Charité, one of the largest university hospitals in Europe and enhances CTGCT’s capabilities for refined transfer of research results to the first-in-human clinical practice and further accessibility of the ATMP as a treatment option for patients.


The pursuit of developing an advanced healthcare ecosystem is not a matter for an individual organization but of the entire community.

The Centre will connect various stakeholders:

  • ACADEmic institutions,
  • industry and the entrepreneurial community,
  • patients’ rights organisations,
  • ngo AND OTHER ORGANISATIONS.

Only in this way can we create advanced therapies that will have high efficacy, will be well accepted, and properly financially supported.

Mol Logotip Dvojezicni Promocijski Cmyk Mali 2

Tplj Logo

Slovenia has high competences in genetic & cell therapies. If we want these competences to create economic effects, we need to make a next step: to establish a center (CTGCT) that would harness the research & business potential. This field is characteristically very complex and very financially intensive. This is not a field that can be established half-heartedly. So strong support is a necessity. Technology park Ljubljana is willing to support the creation and running of such a center. Especially in the field of creation of startups and their growth.

Jernej Pintar, PhD CEO of Technology Park Ljubljana

Advanced therapies are poised to transform healthcare. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide. Currently, Slovenia is lacking the premises that will enable transition of the research of the drug candidates into first in human clinical studies as strict GMP clean rooms, requiring substantial initial investments, are mandatory at that stage. Slovenian scientists have already demonstrated cutting edge expertise in the research of most advanced technologies. The establishment of CTGCT will enable cutting-edge research, development of advanced gene and cell therapy products and clinical stage manufacturing to support first in human studies followed by pivotal clinical research programmes. It will enhance the competitiveness of Slovenia and EU in the field of gene & cell therapy products and create an eco-system attracting talent & big pharma collaborations.

Mateja Urlep, co-founder & CEO Niba Labs

WE RECEIVED LETTERS OF SUPPORT AND EXPRESSIONS OF INTEREST TO COLLABORATE FROM:

Slovensko Združenje Bolnikov Z Limfomom

Satb2 Europe

Cure Gpx4

Hrvatski Savez Za Rijetke Bolesti

Dravet Sindrom

Copac

Norbs Serbia

Slc6a1 Connect

WE RECEIVED LETTERS OF SUPPORT AND EXPRESSIONS OF INTEREST TO COLLABORATE FROM:

Icgeblogo

Sripfull Logo

Eit Health Innostars